Milgamma protect 30 tablets

For diabetes-induced nerve damage (neuropathies) caused by vitamin B1 deficiency effectively relieves tingling, burning and numbness in the feet. Its active substance benfotiamine treats vitamin B1 deficiency as a cause of nerve damage:

well tolerated

lactose-free

gluten-free

non-prescription, only available in pharmacies

Milgamma protect – Your solution to nerve damage caused by diabetes-related vitamin B1 deficiency

People with diabetes often may become aware of their nerve damage through altered sensations like tingling, burning, numbness and pain in the feet. This nerve damage (neuropathies) is often caused by a vitamin B1 deficiency. What starts with slight sensations like tingling or burning, can lead to significant pain and numbness. When heat, cold, pressure and pain are no longer felt, problems can be expected. If foot injuries are not known, they often remain unrecognized and untreated. Various consequences could follow leading up to the ‘diabetic foot syndrome’.

Milgamma protect can contribute to successfully counteracting these nerve disorders. It contains the active substance benfotiamine, a precursor of vitamin B1, that effectively compensates for the vitamin B1 deficiency which is common among diabetic patients.

Milgamma protect compensates the nerve damaging vitamin B1 deficiency and relieves the symptoms of tingling, burning and numbness in the feet. With only 1 tablet per day.

Therapeutic Indications

Treatment of neuropathies and cardiovascular disorders that are caused by vitamin B1 deficiency. Proven therapeutic indications for mono-preparations are exclusively treatment or prophylaxis of clinical vitamin B1 deficiencies, that cannot be corrected through a healthy diet.

Active Substance and Composition

One tablet contains benfotiamine (lipid-soluble vitamin B1 derivative) 300 mg. 

Dosage and Method of Application

The tablets are best taken by swallowing without chewing along with a sufficient amount of fluid.

The duration of administration is determined by the therapeutic response. 

For the treatment of neuropathies, milgamma® protect tablets should be taken initially over a period of at least 3 weeks.

Afterwards, the maintenance treatment is in accordance with the therapeutic response. If you experience little to no improvements after 4 weeks, the treatment should be re-evaluated.

Package Sizes

30 Film-coated Tablets

Obligatory Text

Milgamma protect. Active substance: Benfotiamine. Therapeutic indications: Treatment of neuropathies and cardiovascular disorders that are caused by vitamin B1 deficiency. If you have any questions about the risks and side effects, please read the patient information leaflet and ask your doctor or pharmacist. WORWAG Pharma GmbH & Co. KG, 71034 Boblingen